Form 4: C4 Therapeutics Director Kenneth Anderson Granted 35,500 Stock Options

C4 Therapeutics, Inc. Director Kenneth Carl Anderson was granted 35,500 stock options with an exercise price of $1.44, vesting upon the earlier of June 18, 2026, or the next annual stockholders' meeting.

Summary

• Kenneth Carl Anderson, a Director of C4 Therapeutics, Inc. (Ticker: CCCC), was granted 35,500 stock options on June 18, 2025.
• The exercise price for these stock options is $1.44 per share.
• The options are set to vest in full upon the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Vesting is contingent on Mr. Anderson's continued service as a member of the Board of Directors.
• The stock options have an expiration date of June 17, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event for aligning management incentives with shareholder interests, and it is a routine disclosure for insider transactions.

Positives

• The grant of 35,500 stock options to Director Kenneth Carl Anderson aligns his long-term interests with those of the shareholders, incentivizing performance and retention.

Future Outlook

The granted stock options are set to vest upon the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders, contingent on the director's continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common across all industries for director compensation and retention, and does not inherently reflect broader industry trends.

Corporate Governance

Related Party Transactions

• The document details the grant of 35,500 stock options to Kenneth Carl Anderson, a Director of C4 Therapeutics, Inc., which constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's long-term interests with those of the shareholders, potentially leading to improved company performance.
• Employees: No direct impact on general employees mentioned.

Next Steps

• Vesting of 35,500 stock options upon the earlier of June 18, 2026, or the next annual meeting of C4 Therapeutics, Inc. stockholders, subject to continued service.
• Potential exercise of stock options by Director Kenneth Carl Anderson at an exercise price of $1.44 per share, anytime between vesting and the expiration date of June 17, 2035.

Key Dates

Recommendation

Keywords

C4 Therapeutics, CCCC, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant